82 results
8-K
EX-10.2
SEEL
Seelos Therapeutics Inc
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
covenants and agrees to continue to retain (i) a firm of Public Company Accounting Oversight Board independent registered public accountants
8-K
EX-1.1
SEEL
Seelos Therapeutics Inc
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
as required by the Securities Act and the Securities Act Regulations and the Public Company Accounting Oversight Board. Except as disclosed
8-K
EX-1.1
a27skc6 botrg6o28
12 May 22
Entry into a Material Definitive Agreement
8:31am
8-K
EX-10.1
kr3 y3gjzz
24 Nov 21
Entry into a Material Definitive Agreement
7:27am
8-K
EX-1.1
sb6og0s3 pmw22akj9
21 May 21
Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
12:00am
8-K
EX-1.1
240 m23pgrgfswzelp
26 Jan 21
Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock
5:09pm
8-K
EX-10.1
mjnw4lnc o78q9b0g
17 Dec 20
Entry into a Material Definitive Agreement
4:05pm
424B4
0gri09st
11 Feb 20
Prospectus supplement with pricing info
5:14pm